What's Happening?
The OPTIMA trial, led by researchers at University College London and the University of Glasgow, has shown that a tumor gene expression test can help identify breast cancer patients who can safely avoid chemotherapy. The trial involved over 4,400 women
with HR-positive, HER2-negative breast cancer, using Veracyte's Prosigna assay to measure gene activity. Results presented at ASCO 2026 indicated that patients who did not receive chemotherapy had similar outcomes to those who did, suggesting that many could avoid the treatment's debilitating side effects.
Why It's Important?
Chemotherapy can have significant physical and emotional impacts on patients. The ability to identify those who do not need it could improve quality of life and reduce healthcare costs. This approach represents a move towards more personalized cancer treatment, ensuring that patients receive only the therapies that will benefit them. The trial's findings could lead to changes in treatment protocols, sparing thousands of patients from unnecessary chemotherapy each year.
What's Next?
The next phase of the OPTIMA trial will explore the use of the Prosigna test in younger women to determine if they can also avoid chemotherapy. This research could further refine treatment strategies and expand the benefits of personalized medicine to a broader patient population.
